Treatment of acute myeloid leukaemia in younger patients

This publication has 53 references indexed in Scilit:

• Randomised studies in acute myeloid leukaemia: the double truth
  Bone Marrow Transplantation, 2000
• A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
  British Journal of Haematology, 1999
• A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia
  British Journal of Haematology, 1998
• Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial
  Bone Marrow Transplantation, 1997
• Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia
  The Lancet, 1992
• A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia
  European Journal of Cancer and Clinical Oncology, 1991
• Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens
  Annals of Hematology, 1991
• Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells.
  Journal of Clinical Investigation, 1987
• Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide
  New England Journal of Medicine, 1986
• Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment
  Medical and Pediatric Oncology, 1982